Focus Partners Advisor Solutions LLC Raises Holdings in Natera, Inc. $NTRA

Focus Partners Advisor Solutions LLC grew its position in shares of Natera, Inc. (NASDAQ:NTRA) by 74.6% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,119 shares of the medical research company’s stock after purchasing an additional 2,615 shares during the quarter. Focus Partners Advisor Solutions LLC’s holdings in Natera were worth $1,034,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Natera by 0.6% during the first quarter. Vanguard Group Inc. now owns 12,393,827 shares of the medical research company’s stock worth $1,752,611,000 after purchasing an additional 77,357 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Natera by 56.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock worth $1,490,144,000 after purchasing an additional 3,795,315 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Natera by 9.9% during the first quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company’s stock worth $1,041,055,000 after purchasing an additional 660,538 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Natera by 13.7% during the first quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company’s stock worth $287,908,000 after purchasing an additional 245,719 shares during the last quarter. Finally, Maverick Capital Ltd. grew its holdings in shares of Natera by 19.7% during the first quarter. Maverick Capital Ltd. now owns 1,634,769 shares of the medical research company’s stock worth $231,173,000 after purchasing an additional 268,715 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Trading Down 0.2%

NTRA stock opened at $192.22 on Tuesday. The firm has a 50 day moving average of $171.92 and a 200-day moving average of $160.71. Natera, Inc. has a 12-month low of $117.27 and a 12-month high of $198.99. The company has a market cap of $26.38 billion, a price-to-earnings ratio of -100.64 and a beta of 1.74.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. During the same quarter in the previous year, the business posted ($0.30) earnings per share. Natera’s revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Activity at Natera

In other news, CEO Steven Leonard Chapman sold 1,603 shares of Natera stock in a transaction that occurred on Tuesday, October 21st. The shares were sold at an average price of $187.95, for a total transaction of $301,283.85. Following the completion of the sale, the chief executive officer directly owned 155,855 shares in the company, valued at approximately $29,292,947.25. This trade represents a 1.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John Fesko sold 339 shares of the firm’s stock in a transaction that occurred on Tuesday, October 21st. The stock was sold at an average price of $187.95, for a total transaction of $63,715.05. Following the transaction, the insider directly owned 152,408 shares of the company’s stock, valued at approximately $28,645,083.60. This trade represents a 0.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 57,374 shares of company stock valued at $9,108,022 in the last 90 days. Insiders own 5.63% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on NTRA. BNP Paribas Exane raised Natera from an “underperform” rating to a “neutral” rating and set a $172.00 price target on the stock in a report on Monday. Stephens reissued an “overweight” rating and set a $183.00 price target on shares of Natera in a report on Friday, August 15th. Wells Fargo & Company initiated coverage on Natera in a report on Monday, September 22nd. They set an “equal weight” rating and a $175.00 price target on the stock. Evercore ISI upgraded shares of Natera to a “strong-buy” rating and set a $170.00 price objective for the company in a research report on Monday, July 28th. Finally, Cowen restated a “buy” rating on shares of Natera in a research report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and a consensus price target of $194.89.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.